Evaluation of short programs in a tobacco cessation consultation.

SESSION TITLE: Tobacco Cessation and Prevention PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To analyze and validate 2 month treatment programs, as well as the real dose and time decided by the patient regarding what is recommended and its influence on the tobacco cessation rate.

METHODS: A prospective study including all the patients who attended our tobacco cessation program during the last 6 months. We analyzed several variables: epidemiological, dependence questionnaires, motivation and anxiety/depression questionnaires; cooximetry, recommended dose (varenicline (V): 0.5/1mgrs for 2 months; bupropion (B) only 150 mgrs/day for 2 months), real dose and duration of the treatment, tobacco cessation rates after 3 and 6 months and causes of early abandonment of medication.

RESULTS: We included 312 patients: 175 were treated with V (56%) and 137 with B (44%). By comparing both groups, we couldn't find differences regarding tobacco cessation rate after 3 (V: 64.4% / B: 67.2%) or 6 months (V: 64.2% / B: 67.2%). We realized the patients followed the recommended dose (82.3% with V and 94.2% with B, p=0.001). Cessation rates after 6 months in patients who fulfil the treatment were 53.6% with V and 59% with B). Regarding the duration of treatment: V:6.6±1.6 vs 3.3±1.4 weeks and B:7.9±0.7 vs 3.3±1.8 weeks, p<0.001. As for cessation rates after 6 months: V: 96% vs 51.2%; B: 95.7% vs 6.8%; p<0.001. The most frequent causes of early medication abandonment were economic reasons, psycological dependence and fasle self-control on abstinence symptoms.

CONCLUSIONS: 1. Using 2 month treatments with both varenicline and half the recommended dose of bupropion, cessation rates are very good >64%. 2. Below 5 week treatments are clearly insufficient with bupropion as well as varenicline (worse). 3. Causes of early abandonment of medication were mainly due to economic reasons, psychological dependence and false self-control.

CLINICAL IMPLICATIONS: To improve adherence to tobacco cessation treatment and decreasing early medication abandonment and side effects.

DISCLOSURE: The following authors have nothing to disclose: Ana Gomez-Bastero, Concepcion Romero, Estefania Luque, Virginia Almadana, Soledad Montserrat, Teodoro MontemayorNo Product/Research Disclosure Information.